Archives of Pathology & Laboratory Medicine · 2024 · 27 citations · 26 references
MedicineOncologyPathologyBreast OncologyMolecular OncologyMolecular PathologyCancer ImmunotherapyHer2-positive Breast CancerMetastatic Breast CancerAccuracyDiagnostic Accuracy StudiesDiagnostic Testing AccuracyHer2 ExpressionHer2 Gene AmplificationInter-rater AgreementMetastatic Breast Cancer TreatmentRater Agreement
CONTEXT.—: Recently, a new type of antibody-drug conjugate, trastuzumab-deruxtecan (T-DXd), has been approved for the treatment of metastatic breast cancer with low level of human epidermal growth factor receptor 2 (HER2) gene expression. Thereby, eligibility relies on an accurate diagnosis of HER2-low status defined by immunohistochemistry IHC 1+/2+ with no gene amplification. OBJECTIVE.—: To assess pathologists' accuracy and training efficacy in the diagnosis of HER2-low. DESIGN.—: Agreement rates of HER2-low scoring in breast cancer tissue were assessed between expert consensus and real-world pathologists (n = 77 from 14 countries) before and after a specific 4-hour training program for HER2-low detection. Two assays were evaluated, the Ventana Pathway 4B5 CDx and the Dako HercepTest (polyclonal). Concordance of the pathologists with consensus score and efficacy of training were measured by Cohen κ, overall rater agreement, and receiver operating characteristic (ROC) curve statistics. RESULTS.—: In the Ventana 4B5 HER2-low category, baseline agreement rates were >80% but <90%. Negative percentage agreement was improved from 80.6% to 91.1% by training. In the HER2-0 category, positive percentage agreement (74.6%) was the only parameter below the 80% benchmark but was significantly improved to 89.2% after training. Training efficacy was confirmed by ROC curve analysis, which shows improvement for the identification of HER2-0 and HER2-low cases. Finally, in-depth examination of cases with discordant HER2 status disclosed specific issues of HER2-low underscoring and overscoring. CONCLUSIONS.—: The ability of pathologists to achieve acceptable diagnostic accuracy in identifying patients with HER2-low breast cancer could be enhanced by short-term training. Potential routes to improve the quality of HER2-low scoring in clinical practice have been identified.
26
The Measurement of Observer Agreement for Categorical Data
J. Richard Landis, Gary G. Koch · Biometrics · 1977 · 78.9K citations · Full text
Interrater reliability: the kappa statistic
Marry L. McHugh · Biochemia Medica · 2012 · 18.6K citations · Full text
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Shanu Modi, William Jacot, Toshinari Yamashita et al. · New England Journal of Medicine · 2022 · 2.5K citations · Full text
Medicine, Oncology, Pharmacology +17
Antonio C. Wolff, M. Elizabeth H. Hammond, Jared N. Schwartz et al. · Archives of Pathology & Laboratory Medicine · 2007 · 1.9K citations
Antonio C. Wolff, M. Elizabeth Hammond, Kimberly H. Allison et al. · Archives of Pathology & Laboratory Medicine · 2018 · 1.5K citations · Full text